AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US

Benzinga2022-01-13

AstraZeneca Plc said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.

  • The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.
  • The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.
  • In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.
  • The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
  • The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.
  • Price Action: AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
5